Switching to Abemaciclib May Improve Outcomes After Disease …
Jul 10, 2024 — Real-world evidence suggests that use of abemaciclib after disease progression on a prior CDK4/6 inhibitor may extend progression-free survival, although phase II trials with CDK4/6 inhibitors aside from abemaciclib have generated mixed results.
FDA expands early breast cancer indication for abemaciclib with ...
On March 3, 2023, the Food and Drug Administration (FDA) approved abemaciclib (Verzenio, Eli Lilly and Company) with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant ...
Abemaciclib May Be Option for Early-Stage Breast Cancer
Jan 6, 2021 — Updated results from a large study suggest that the drug abemaciclib (Verzenio) may be a new treatment option for people with the most common type of breast cancer. Nearly 90% of people diagnosed with breast cancer have early-stage disease. And most of the time the cancer is classified as HR positive and HER2 negative.
Efficacy of abemaciclib plus ET for HR+/HER2–breast cancer
Sep 24, 2024 — Results from the ABIGAIL study showed that the CDK 4/6 inhibitor abemaciclib combined with endocrine therapy (ET) achieved a higher early overall response rate (ORR) at 12 weeks compared to standard chemotherapy as first-line treatment in patients with hormone receptor–positive (HR+)/HER2-negative advanced breast cancer with aggressive ...
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone …
Jan 9, 2024 — Two years of adjuvant abemaciclib combined with endocrine therapy (ET) resulted in a significant improvement in invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS) that persisted beyond the 2-year treatment period in patients with hormone receptor–positive, human epidermal growth factor receptor 2–negative, node ...
FDA approves abemaciclib with endocrine therapy for early breast …
On October 12,2021, the Food and Drug Administration approved abemaciclib (Verzenio,Eli Lilly and Company)with endocrine therapy (tamoxifen or an aromatase inhibitor) for adjuvant treatment of...
News Release - Eli Lilly and Company
INDIANAPOLIS, Oct. 13, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Eli Lilly and Company's (NYSE: LLY) Verzenio ® (abemaciclib), in combination with endocrine therapy (tamoxifen or an aromatase inhibitor), for the adjuvant treatment of adult patients with hormone receptor-positive (HR+), human epidermal growth ...
MonarchE Update: Benefit of Abemaciclib Increases Over Time
Dec 11, 2022 — Results of a planned interim overall survival analysis of the phase III monarchE trial offer further support for the addition of abemaciclib to adjuvant endocrine therapy for patients with hormone receptor–positive, HER2-negative, node-positive, high-risk breast cancer, according to Stephen R.D. Johnston, MD, PhD, of the Royal Marsden NHS ...
FDA Approves Abemaciclib with Endocrine Therapy for Early …
On October 12, 2021, the Food and Drug Administration approved abemaciclib (Verzenio, Eli Lilly and Company) with endocrine therapy (tamoxifen or an aromatase inhibitor) for adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at ...
Abemaciclib as initial therapy for advanced breast cancer
Jun 22, 2021 — In MONARCH 3, continuous dosing of abemaciclib with an aromatase inhibitor (AI) conferred significant clinical benefit to postmenopausal women with HR+, HER2− advanced breast cancer.